One biotechnology and drugs player that insiders are buying a large amount of stock in is
(AEGR - Get Report)
. This company focused on the development and commercialization of therapeutics to treat lipid disorders. Insiders are buying this stock into strength, since shares are up over 40% in the last three months.
Aegerion Pharmaceuticals has a market cap of $29 million and an enterprise value of $450 million. Its estimated growth rate for this year is -20.6%, and for next year it's pegged 26.2%. This is a cash-rich company, since the total cash position on its balance sheet is $95.46 million and its total debt is $10.53 million.
A beneficial owner just
bought 180,000 shares, or $3.86 million worth of stock, at $19.50 to $22.71 per share.
From a technical perspective, AEGR is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been trending sideways for the last month and change, with shares moving between $18.33 on the downside and $23 on the upside. A high-volume move outside of that range soon will likely lead to the next major trend for shares of AEGR.
If you're bullish on AEGR, then I would look for long-biased trades once this stock manages to break out above some near-term overhead resistance levels at $22.98 to $23 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 459,973 shares. If that breakout triggers soon, then AEGR will set up to re-test or possibly take out its next major overhead resistance level at $25.92 a share. Keep in mind that traders can also buy AEGR off weakness to anticipate that breakout as long as shares continue to trend above its 50-day at $19.04 a share.
Another name in the communications equipment complex that insiders are active in here is
(JNPR - Get Report)
. This company designs, develops and sells innovative products and services that together provide its customers with high-performance network infrastructure built on simplicity, security, openness and scale. Insiders are buying this stock into some modest weakness, since shares are off by 11% so far in 2012.